NR1H4 and type 2 diabetes mellitus: Metformin is a first-line drug for T2DM and Sun et al. [37] found that metformin treatment decreased the abundance of Bacteroides fragilis and increased the level of GUDCA in the intestine, thereby inhibiting intestinal FXR signaling and the synthesis of liver glycogen.